ASTRO Recommends Avoiding Adjuvant WBRT When Treating Brain Mets.  As a part of the Choosing Wisely campaign, the American Society for Radiation Oncology (ASTRO) has recently updated their evidence-based recommendations of ‘Things Providers and Patients Should Question.’ They recommend that physicians avoid routinely adding adjuvant whole brain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) for treating limited brain metastases. Studies have demonstrated the addition of adjuvant WBRT to SRS is associated with diminished cognitive function and worse patient-reported fatigue and quality of life.

To read the ASTRO “Ten Things Physicians and Patients Should Question” list in its entirety, go to: